Sun Pharmaceutical Industries Ltd. closed 14.47% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

Sun Pharmaceutical Industries Ltd. closed 14.40% short of its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

What's driving this $370 million transformation? The global residual DNA testing market, valued at US$0.27 billion in 2024, ...

June 13 (Reuters) - Sun Pharmaceutical (SUN.NS), opens new tab, India's largest drugmaker by revenue, on Friday named Kirti Ganorkar as managing director, effective September 1. The company's ...

Pharma Stocks in News, Sun Pharma Share Price, Zydus Lifesciences Share Price: Shares of two major pharmaceutical industries companies - Sun Pharmaceutical Industries and Zydus Lifesciences - are in ...

Sun Pharma and its partner, Sun Pharma Advanced Research Company Ltd. (SPARC), will assess next steps regarding the SCD-044 asset, though no further trials are planned at this time.

Sun Pharmaceutical Industries is discontinuing two trials of its drug candidate SCD-044 for moderate to severe psoriasis and atopic dermatitis, as they did not meet the primary endpoints.

Sun Pharmaceuticals’ share price fell 4.77% to an intraday low of Rs 1,636.60 on the National Stock Exchange (NSE). The decline came after the company reported weak quarterly earnings, with its ...

In his 42-year journey of building Sun Pharma from the ground up, there is only one thing Dilip Shanghvi would do differently. “Sometimes I would have got angry… That I wouldn’t have wanted ...

Sun Pharma said it will disclose its launch plans in due course of time. Leqselvi or deuruxolitinib is used to treat alopecia areata, an auto-immune condition that causes hair-loss, and it affects ...

The Elliott Wave analysis for SUN PHARMACEUTICAL on the daily chart reveals a bullish trend, now approaching its late stage. The focus is on navy blue wave 5, which completes the broader gray wave ...

Nifty Pharma delivered a close to 20% return during Trump’s first term (Jan-2017 to Jan-2021) vs. Nifty 50’s absolute return of 80%. Large-cap stocks such as Cipla tumbled 16% between 2017 and ...